Analysts Set Annexon, Inc. (NASDAQ:ANNX) Target Price at $16.00

Posted by on Jul 12th, 2026

Shares of Annexon, Inc. (NASDAQ:ANNX – Get Free Report) have received a consensus rating of “Hold” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $16.00.

ANNX has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Annexon in a research note on Monday, April 20th. Chardan Capital reaffirmed a “buy” rating and issued a $16.00 target price on shares of Annexon in a report on Friday, March 20th. The Goldman Sachs Group began coverage on shares of Annexon in a research note on Tuesday, May 12th. They issued a “neutral” rating and a $7.00 target price on the stock. Finally, Wall Street Zen upgraded shares of Annexon from a “sell” rating to a “hold” rating in a report on Saturday, May 9th.

View Our Latest Report on ANNX

Insider Buying and Selling

In other Annexon news, Director William H. Carson acquired 8,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average cost of $5.78 per share, with a total value of $46,240.00. Following the completion of the transaction, the director directly owned 78,405 shares of the company’s stock, valued at approximately $453,180.90. This represents a 11.36% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Muneer A. Satter acquired 613,497 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The shares were acquired at an average cost of $5.41 per share, for a total transaction of $3,319,018.77. Following the completion of the transaction, the director directly owned 10,342,134 shares of the company’s stock, valued at $55,950,944.94. The trade was a 6.31% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 10.31% of the stock is owned by insiders.

Hedge Funds Weigh In On Annexon

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Rhenman & Partners Asset Management AB grew its position in shares of Annexon by 78.9% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 823,000 shares of the company’s stock valued at $2,510,000 after acquiring an additional 363,000 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in Annexon during the first quarter valued at about $7,312,000. BVF Inc. IL increased its position in Annexon by 30.4% in the fourth quarter. BVF Inc. IL now owns 9,128,080 shares of the company’s stock worth $45,823,000 after buying an additional 2,128,080 shares in the last quarter. Ishara Investments LP bought a new position in shares of Annexon in the fourth quarter worth about $3,765,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Annexon during the 4th quarter valued at about $82,000.

Annexon Price Performance

ANNX stock traded down $0.14 on Friday, reaching $5.80. 2,736,860 shares of the company traded hands, compared to its average volume of 4,683,193. The firm has a fifty day simple moving average of $5.36 and a 200-day simple moving average of $5.55. The company has a market cap of $950.27 million, a P/E ratio of -4.75 and a beta of 1.16. Annexon has a one year low of $2.03 and a one year high of $7.18.

Annexon (NASDAQ:ANNX – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.07. On average, sell-side analysts forecast that Annexon will post -0.92 EPS for the current year.

About Annexon

(Get Free Report)

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.

Featured Articles

Analyst Recommendations for Annexon (NASDAQ:ANNX)

Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.